Osteoporosis Treatment Market

The increasing prevalence of osteoporosis among aged population is anticipated to openup the new avenue for Osteoporosis Treatment Market

by

The Osteoporosis Treatment Market is estimated to be valued at US$ 14.54 Bn in 2023 and is expected to exhibit a CAGR of 3.8% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market Overview:

Osteoporosis is a bone disease that weakens bones and makes them prone to fracture. It is characterized by low bone mass and microarchitectural deterioration of bone tissue. Common osteoporosis treatments include medicines that slow bone loss such as bisphosphonates, parathyroid hormone treatments and RANK ligand inhibitors. These treatments help maintain bone density and reduce the risk of fractures.

Market Dynamics:

The increasing geriatric population and rising incidences of osteoporosis drive the growth of the osteoporosis treatment market. As per WHO, by 2050, the world’s population aged 60 years and older will total 2 billion, up from 900 million in 2015. Age is one of the primary risk factors for osteoporosis. Moreover, factors such as rising sedentary lifestyle, lack of exercise and vitamin D deficiency are contributing to the increasing prevalence of osteoporosis globally. This is expected to raise the demand for osteoporosis treatments over the forecast period.

Another key driver is the growing preference for osteoporosis therapies such as bisphosphonates and parathyroid hormone treatments over traditional treatment options such as calcium and vitamin D supplements. Bisphosphonates are the gold standard for osteoporosis treatment and their widespread adoption is fueling market growth.

Segment Analysis

The global osteoporosis treatment market is dominated by the drug therapy segment. The drug therapy segment accounts for over 70% of the market share owing to the growing prevalence of osteoporosis across the world and high adoption of drug therapies due to ease of administration compared to other therapies. Within drug therapy, bisphosphonates dominate the segment and account for over 50% of drug therapy sales. Increased effectiveness, affordability and easy availability of bisphosphonate drugs are key factors responsible for the dominant position of this sub-segment.

PEST Analysis

Political: Governments across various countries are raising awareness about osteoporosis prevention and treatment through campaigns. Favorable regulatory environment and reimbursement policies are boosting the adoption of osteoporosis treatment options.
Economic: Rising geriatric population and increasing healthcare spending are fueling market growth. However, high cost of branded therapies remains a challenge.
Social: Growing knowledge about osteoporosis risks and treatment options is driving the demand. Sedentary lifestyle among many is also raising the risk of osteoporosis.
Technological: Advancements in drug delivery systems and 3D printing technologies for personalized implants are expanding treatment solutions and driving market growth.

Key Takeaways

The Global Osteoporosis Treatment Market Size is expected to witness high growth, exhibiting CAGR of 3.8% over the forecast period, due to increasing geriatric population globally prone to age-related osteoporosis. The market size for 2023 is US$ 14.54 Bn.

North America dominates the global osteoporosis treatment market with over 40% share owing to high awareness, diagnosed cases and availability of advanced treatment options. Asia Pacific exhibits high growth potential and is emerging as the fastest-growing regional market due to growing aging population, increasing prevalence of osteoporosis and improving access to diagnosis and treatment in the region.

Key players operating in the osteoporosis treatment market are Teva Pharmaceutical Industries Ltd., DAIICHI SANKYO COMPANY, LIMITED, Amgen Inc., Dr. Reddy’s Laboratories Ltd., Viatris Inc., Ligand Pharmaceuticals Incorporated, Eli Lilly and Company, Asahi Kasei Corporation, F. Hoffmann-La Roche Ltd, EffRx Pharmaceuticals SA, Novartis AG, Merck & Co., Inc., GSK plc., and Pfizer Inc. Major players are focusing on developing advanced drugs and combination therapies to strengthen their market position.

*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it